

Turkish Journal of Medical Sciences

http://journals.tubitak.gov.tr/medical/

A comparison of mycophenolate mofetil and calcineurin inhibitor as maintenance immunosuppression for kidney transplant recipients: A meta-analysis of randomized controlled trials

Jin DENG^{1,*}, Yi LU¹, Lihong HE², Jihong OU¹, Hongping XIE³

¹Department of Health Management, the First Affiliated Hospital of University of South China, Hengyang, China ²Department of Nephrology, the First Affiliated Hospital of University of South China, Hengyang, China ³Department of Diagnostic Ultrasound, the First Hospital of Changsha

Received: 21.10.2019	•	Accepted/Published Online: 26.12.2020	•	Final Version: 28.06.2021
----------------------	---	---------------------------------------	---	---------------------------

Background/aim: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the comparison and its timing between mycophenolate mofetil (MMF) and calcineurin inhibitor (CNI) as maintenance immunosuppression for kidney transplant recipients.

Materials and methods: The RCTs of MMF versus CNI as maintenance immunosuppression for kidney transplant recipients were searched from PubMed, Embase, Cochrane Central Register of Controlled Trials (CCRCT), and ClinicalTrials.gov. After screening relevant RCTs, two authors independently assessed the quality of included studies and performed a meta-analysis using RevMan5.3. Relative risk (RR) was used to report dichotomous data, while mean difference (MD) with 95% confidence interval (CI) was used to report continuous outcomes. The analysis was conducted using the random-effect model due to the expected heterogeneity among different studies. Four subgroups were allocated to compare MMF with CNI as maintenance immunosuppression: (1) after 3 months of CNI-based therapy, (2) after 6 months of CNI-based therapy, (3) after 12 months of CNI-based therapy, and (4) in recipients with allograft dysfunction.

Results: Twelve RCTs with 950 renal transplant recipients were included. This meta-analysis presented the following results upon comparison between MMF and CNI as maintenance immunosuppression for kidney transplant recipients: (1) MMF significantly improved the glomerular filtration rate (GFR) not only in the comparison performed after 3, 6, or 12 months of CNI-based therapy but also in the comparison of recipients with allograft dysfunction, (2) MMF may increase the risk of acute rejection in the comparison performed after 3 months of CNI-based therapy, but no increase was noted in the comparison performed after 6 or 12 months of CNIbased therapy.

Conclusion: Our present meta-analysis suggested that MMF followed at least 6 months of CNI-based therapy is an effective maintenance immunosuppressive regimen for kidney transplant recipients to improve renal function but not increase rejection.

Key words: Kidney transplantation, mycophenolate mofetil, calcineurin inhibitor, meta-analysis

1. Introduction

End-stage renal disease (ESRD) is a chronic, irreversible decline in kidney function that severely and deleteriously affects the duration and quality of life of patients. Approximately1.9million patients receiver enal replacement therapy (RRT) worldwide [1]. RRT, which includes kidney transplantation (KT), hemodialysis (HD), and peritoneal dialysis (PD), is the only option for individuals with ESRD to survive at present. Compared to dialysis, KT prolongs the life-span, improves renal function and quality of life, and is more cost-effective [2-5]. Nevertheless, a suitable and effective immunosuppressive regimen that minimizes

acute rejection (AR) and limits adverse events (AEs) is paramount for KT success. Regarding immunosuppressive therapy, calcineurin inhibitors (CNIs), such as cyclosporine A (CsA) or tacrolimus (TAC), have served as fundamental therapies for renal allograft recipients since CsA became available in the early 1980s. However, significant AEs, such as hypertension, dyslipidemia, new-onset diabetes after transplantation (NODAT), and particularly nephrotoxicity of CNI, have been noted and they serve as major causes of later graft loss [6]. Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), which inhibits T and B lymphocyte proliferation, has

^{*} Correspondence: dengjin618@163.com 1080

been shown to reduce the risk of acute allograft rejection and lack nephrotoxicity [7,8]. Moreover, a meta-analysis demonstrated the positive effect of CNI sparing with MMF as solo adjunctive immunosuppressive agents after KT [9]. Several randomized controlled trials (RCTs) compared the outcomes after MMF or CNI withdrawal in renal transplant recipients [10-12]. However, to date, meta-analysis data are not available to compare the efficacy and safety of MMF with CNI as maintenance immunosuppression for kidney transplant recipients. In addition, given the correlation between the duration of CNI and its therapeutic efficacy and side effects, we conducted a systematic review and meta-analysis of RCTs to evaluate the comparison and its timing between MMF and CNI as maintenance immunosuppression for kidney transplant recipients.

2. Materials and methods

2.1. Search strategy

PubMed, Embase, Cochrane Central Register of Controlled Trials (CCRCT), and ClinicalTrials.gov were searched without language restrictions using the following mesh terms and entry terms: kidney transplantation, renal transplantations, kidney grafting, mycophenolate mofetil, mycophenolate sodium, cellcept, calcineurin inhibitors, protein phosphatase-2b inhibitors, calcineurin antagonists, cyclosporine, cyclosporine a, tacrolimus, and FK506 (all to September 2019). We retrieved the reference lists of all relevant trials and consulted experts in the field to identify potentially relevant studies.

2.2. Inclusion criteria

For inclusion in this meta-analysis, studies had to meet the following criteria: (1) Only RCTs were considered, (2) Patients received renal transplant from a living or deceased donor, (3) Studies compared the outcomes of the use of MMF to CNI as maintenance immunosuppression for kidney transplant recipients, (4) Trials analyzed primary outcomes, including renal function, acute rejection, graft survival, or patient survival. Studies with complete CNI avoidance in de novo patients or multiple organ transplant recipients were excluded. The studies were subsequently allocated to four subgroups to compare MMF and CNI as maintenance immunosuppression: (1) after 3 months of CNI-based therapy, (2) after 6 months of CNI-based therapy, (3) after 12 months of CNI-based therapy; and (4) in recipients with allograft dysfunction.

2.3. Study selection

Two authors separately examined the titles and/or abstracts of each study and excluded irrelevant trials. Subsequently, the full text of all articles was scanned and evaluated independently by two authors strictly according to the inclusion criteria. All disagreements regarding study eligibility for inclusion were discussed to achieve a consensus.

2.4. Data extraction

Two authors independently extracted data on the baseline demographic characteristics of participants, study design, intervention and control treatment, and outcome data of studies. We contacted the trial authors or sponsors directly to obtain the required information if data were unavailable. When disagreements occurred, the third author provided an opinion to resolve the issue.

2.5. Study quality assessment

Two authors independently evaluated the quality of the included studies. Disagreements were resolved by consensus. The quality of included studies was evaluated by the Cochrane Handbook [13]. The risk of bias comprised a description and judgment for the following criteria: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, other source of bias. Each criterion was judged 'low risk of bias', 'unclear risk of bias', or 'high risk of bias'.

2.6. Statistical analysis

Outcomes were analyzed using Cochrane Review Manager Software (RevMan5.3, Copenhagen, Denmark: the Nordic Cochrane Centre, the Cochrane Collaboration). Continuous variables are expressed as the mean difference (MD) and 95% confidence interval (CI). The risk ratio (RR) and 95%CI were calculated for dichotomous data. If there are no events in one arm or two arms, the data also will be filled truthfully in the forest figures. The I²statistic and Chi-squared test were used to assess the heterogeneity of the included studies (I²>50% and p<0.1 indicated significant heterogeneity)[14]. If significant heterogeneity was present among trials, the random-effect model was used. Otherwise, the fixed-effect model was used. Publication bias was evaluated using a funnel plot.

3. Results

3.1. Literature selection

The literature search is presented in Figure 1. A total of 2350 articles were retrieved, and 2324 studies were excluded after examining the titles and abstracts. After reading the full text of the remaining 26 trials, we identified 12 eligible studies for inclusion in the meta-analysis that strictly fulfilled the inclusion and exclusion criteria. Three trials investigated comparison after 3 months of CNI-based therapy [12,15,16], two trials investigated comparison after12 months of CNI-based therapy [10,18,19], and four trials that investigated comparison in recipients with allograft dysfunction [20–23].




Figure 1. Flow chart of literature selection.

3.2. Study characteristics and quality assessment

A total of 950 eligible renal transplant recipients were included in the meta-analysis, of whom 497 were treated with MMF, and 453 were treated with CNI. All studies reported randomization. Six studies reported random sequence generation and allocation concealment [11,17,18,20,21,23]; however, no studies referred to double-blinding. The baseline characteristics of the included studies are summarized in Table 1, and the risk of bias are showed in Figure 2.

3.3. Glomerular filtration rate

Nine studies that reported changes of the GFR were included in the meta-analysis. Compared to CNI, MMF significantly improved the GFR after CNI-based therapy (MD 8.47, 95%CI (7.79, 9.14), p < 0.00001) (Figure 3). Subgroup analysis showed similar effects in comparison after 3, 6, or 12 months of CNI-based therapy (3 months: MD 10.11, 95%CI (5.77, 14.46), p < 0.00001; 6 months: MD 8.40, 95%CI (7.71, 9.09), p < 0.00001 or 12 months: MD 19.00, 95%CI (5.02, 32.98), p = 0.008) (Figure 3).

Subanoun	Stor day	N	Mean age (year	rs)*	Sex	Intervention	Duration
Subgroup	Study	N	Recipient	donor	(M/F)	Intervention	(M)
Comparison	Hoerning 2012	T: 6 C: 8	T: 46 ± 9.8 C: 60 ±11.5	_	T: 2/4 C: 3/5	MPA +CsA +Bas+ CS for 3 mo, then T: EVL+ CS+ MPA (0.72g b.i.d); C: EVL+CS+ Low-CsA (target level:50– 75ng/mL)	12
after 3 months of CNI-based therapy	Hazzan 2005	T: 54 C: 54	T: 45.1 ± 11.2 C: 42.5 ± 12.1	T: 40.0 ± 14.0 C: 36.7 ± 13.1	T: 32/22 C: 36/18	MMF+ CsA + ATG+ CS for 3 mo, then T: CS+ MMF (2g q.d); C: CS+ CsA (target level:100–300ng/mL)	12
	Schnulle 2002	T: 44 C: 40	T: 44.7 ± 13.3 C: 51.3 ± 11.5	T: 40.7 ± 15.3 C: 47.7 ± 15.4	T: 32/12 C: 22/18	MMF+ CsA + CS for 3 mo, then T: CS+ MMF (1g b.i.d); C: CS+ CsA (target level:100–250ng/mL)	12
Comparison after 6	Stevens 2014	T:90 C:88	T:47.9 ± 12.1 C:46.5 ± 11.6	T: 39.3 ± 13.1 C: 42.6 ± 12.1	T: 62/28 C: 59/29	TAC+ SRL+ATG+ CS for 6 mo, then T: SRL+ MMF (1g b.i.d); C: SRL+ TAC (target level:2–4ng/mL)	24
months of CNI-based therapy	Mourer 2012	T: 79 C: 79	T: 52.5 ± 10.8 C: 52.7 ± 13.0	T: 43.3 ± 16.6 C: 42.5 ± 14.4	T: 56/23 C: 54/25	MMF+ CsA or TAC + CS for 6 mo, then T: CS+ MMF (AUC:75ug.hr/ml); C: CS+ CsA (AUC3250ng.hr/ml) or TAC (AUC120ng.hr/mL)	36
	Asberg 2013	T: 20 C: 19	T: 63.0 ± 11.2 C: 56.4 ± 13.4	_	T: 12/8 C: 14/5	MMF+ CsA+ CS for 12 mo, then T: CS+ MMF (2g q.d); C: CS+ CsA (target level:75–125ng/mL)	12
Comparison after 12 months of CNI-based therapy	Albano 2012	T:15 C:15	T:58.8 ± 7.6 C:62.3 ± 9.5	T: 64.7 ± 12.0 C: 62.9 ± 9.8	T: 13/2 C: 11/4	CsA +EVL+ CS for 12 mo, then T: EVL+ CS+ MMF (0.72g b.i.d); C: EVL+ CS+ CsA (target level:200–450ng/ mL)	12
шстару	Cransberg 2007	T: 18 C: 18	T: 11.9ª C: 10.9ª	_	T: 8/10 C: 14/4	MMF+ CsA+ CS for 12 mo, then T: CS+ MMF (0.6g b.i.d); C: CS+ CsA (target level:150–200ng/mL)	24
	Frimat 2006	T:70 C: 31	T:43.8 ± 10.6 C:44.7 ± 11.1	_	T:55/15 C:27/4	T: MMF (2g q.d) +half dose of CsA (target level: not available) C: CsA standard- dose (target level:>80ng/mL)	24
Comparison in allograft	Dudley 2005	T: 73 C: 70	T:43(18-63) ^b C:43(18-63) ^b	T:43.8(13-72) ^b C:34.8(10-65) ^b	T: 45/28 C: 44/26	T:CS+ MMF (2g q.d) C: CsA-based standard therapy (target level:>80ng/mL)	14
dysfunction recipients	Stoves 2004	T: 13 C: 16	_	_	_	T: MMF (1g b.i.d) + reduced dose of CsA (target level:75–100ng/mL) C: CsA standard- dose (target level: unit standard)	6
	Mcgrath 2001	T: 15 C: 15	T: 50.4 ± 8.3 C: 42.6 ± 3.1	T: 41.8 ± 5.0 C: 40.9 ± 2.7	T: 10/5 C: 10/5	T: MMF+ CS (2g q.d) C: AZA+ CS+ TAC (target level:8–12ng/ mL)	8

MMF, mycophenolate mofetil; CNIs, calcineurin inhibitors; CsA, cyclosporine A; TAC, tacrolimus; TAC-Elim, TAC-elimination; SRL, sirolimus; ATG, antithymocyte globulin; Bas, basiliximab; Dac, daclizumab; EVL, everolimus; AZA, azathioprine; MPA, mycophenolate sodium; CS, corticosteroids; KT: kidney transplantation. *Data are represented as mean ± standard deviation (SD); — means data deficiency; T, treatment group; C, control group; N, number; ^a Values were expressed as mean; ^b Values were mean (range); AUC, area under the time-blood concentration curve.

HONG et al. / Turk J Med Sci




Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Furthermore, MMF also significantly improved the GFR in comparison of recipients with allograft dysfunction compared with CNI (MD 7.20, 95%CI (4.09, 10.32), p < 0.00001) (Figure 3).

3.4. Graft loss

No significant difference in graft loss (including death) was observed between the MMF group and the CNI group after CNI-based therapy (RR 1.01, 95%CI (0.62, 1.67), p = 0.95). Subgroup analysis showed similar effects in comparison after 3, 6, or 12 months of CNI-based therapy (3 months: RR 2.73, 95%CI (0.11, 65.24), p = 0.53; 6 months: RR 0.68, 95%CI (0.32, 1.42), p = 0.30 or 12 months: RR 1.60, 95%CI (0.80, 3.23), p = 0.19). Similar effect was also seen in comparison of recipients with allograft dysfunction (RR 0.91, 95%CI (0.36, 2.33), p = 0.84). The fixed-effect model was used for the meta-analysis given that no heterogeneity was noted among the included studies. One study was excluded for analysis due to the absence of graft loss data [15]. The results are presented in Figure 4.

3.5. Mortality

Eleven included studies reported mortality data. There were no significant differences in mortality between the MMF and CNI groups after CNI-based therapy (RR 0.71, 95%CI (0.37, 1.35), p = 0.30). Subgroup analysis showed similar effects in comparison after 3, 6, or 12 months of CNI-based therapy (3 months: could not be estimated; 6 months: RR 0.63, 95%CI (0.25, 1.58), p = 0.33 or 12 months: RR 0.82, 95%CI (0.34, 2.01), p = 0.67). Moreover, there was also no significant difference in mortality between the MMF and CNI groups in comparison of recipients with allograft dysfunction (RR 6.72, 95%CI (0.35, 127.71), p = 0.21). The fixed-effect model was used given the lack of heterogeneity among the studies. The results are presented in Figure 5.

3.6. Acute rejection

MMF was associated with increased episodes of acute rejection (biopsy proven) compared with CNI after CNIbased therapy (RR 2.05, 95%CI (1.27, 3.32), p = 0.003). Similar effect was seen in comparison after 3 months of CNI-based therapy (RR 2.90, 95%CI (1.10, 7.64), p = 0.03) when subgroup analysis was performed. However, no significant differences in acute rejection were found between the MMF and CNI groups for comparison after 6 or 12 months of CNI-based therapy (6 months: RR 1.59, 95%CI (0.83, 3.02), p = 0.16 or 12 months: RR 2.51, 95%CI (0.81, 7.72), p = 0.11). No acute rejection episodes occurred in recipients with allograft dysfunction. The fixed-effect model was used given the lack of heterogeneity among the studies. The results are presented in Figure 6.

3.7. Adverse events

A comparison of adverse events in the MMF and CNI groups is shown in Table 2. The random-effect model was used if significant heterogeneity (I²>50% and p < 0.1) was presented among studies. Otherwise, the fixed-effect model was used instead. The results indicated that MMF reduced the occurrence rate of proteinuria (RR 0.63, 95%CI (0.43, 0.92), p = 0.02), although the opposite effects were presented for anemia (RR 2.36, 95%CI (1.46, 3.81), p = 0.0005) and diarrhea (RR 5.36, 95%CI (2.66, 10.80), p = 0.00001). The incidence rates of infection, NODAT, malignancies, and hypertension were similar between the MMF and CNI groups.

3.8. Publication bias

A funnel plot of acute rejection was examined to evaluate publication bias. As shown in Figure 7, no publication bias was observed.

		MMF	_		CNI	_		Mean Difference	Mean Difference
Study or Subgroup	The second		Total		SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
1.1.1 Comparison after									
Albano 2012	55	18	14	36	19	13	0.2%	19.00 [5.02, 32.98]	
Hazzan 2005		18.7	54	56.5	18	54	1.0%	8.20 [1.28, 15.12]	
Hoerning 2012		14.4	6		19.7	8		11.90 [-5.96, 29.76]	
Mourer2012	59.5	2.1	71	51.1	2.1	73	97.3%	8.40 [7.71, 9.09]	
Schnulle 2002	73.2	14.9	41	61.9	11.8	39	1.3%	11.30 [5.42, 17.18]	<u> </u>
Subtotal (95% CI)			186			187	100.0%	8.47 [7.79, 9.14]	•
Heterogeneity: Chi ² = 3	.26, df	= 4 (P	= 0.52);	$ ^2 = 0^{\circ}$	6				
Test for overall effect: 2	Z = 24.5	2 (P <	0.0000	1)					
1.1.2 Comparison afte	er 3 mo	of CN	II-based	thera	ру				
Hazzan 2005	64.7	18.7	54	56.5	18	54	39.4%	8.20 [1.28, 15.12]	
Hoerning 2012	54.8	14.4	6	42.9	19.7	8	5.9%	11.90 [-5.96, 29.76]	
Schnulle 2002	73.2	14.9	41	61.9	11.8	39	54.7%	11.30 [5.42, 17.18]	
Subtotal (95% CI)			101			101	100.0%	10.11 [5.77, 14.46]	•
Heterogeneity: Chi ² = 0	.49, df	= 2 (P	= 0.78);	$ ^2 = 0^9$	6				
Test for overall effect: 2	Z = 4.56	(P <)	0.00001)					
		1.		, ,					
1.1.3 Comparison after					-				
Mourer2012	59.5	2.1	71	51.1	2.1		100.0%	8.40 [7.71, 9.09]	
Subtotal (95% CI)			71			73	100.0%	8.40 [7.71, 9.09]	,
Heterogeneity: Not app									
Test for overall effect: 2	2 = 24.0	0 (P <	0.0000	1)					
1.1.4 Comparison afte	er 12 m	o of C	NI-base	d ther	ару				_
Albano 2012	55	18	14	36	19	13	100.0%	19.00 [5.02, 32.98]	
Subtotal (95% CI)			14			13	100.0%	19.00 [5.02, 32.98]	
Heterogeneity: Not app	licable								
Test for overall effect: 2	z = 2.66	(P =)	0.008)						
1.1.5 Comparison for	allogra	ft dys	functio	n					
Dudley 2005	-	10.9	61		11.1	55	60.3%	5.50 [1.49, 9.51]	
Frimat 2006		16.6	53		16.4	27	16.6%	11.10 [3.47, 18.73]	
Mcgrath 2001		12.8	15	23.2	8.5	15	16.0%	11.50 [3.72, 19.28]	
Stoves 2004		15.3	11		15.2	16	7.1%	2.80 [-8.91, 14.51]	
Subtotal (95% CI)	0L.L	1010	140	2011	. O.L		100.0%	7.20 [4.09, 10.32]	•
Heterogeneity: Chi ² = 3	.41. df	= 3 (P	= 0.33)	$ ^2 = 12$	%	0.015			
Test for overall effect: 2		•	,.						
		(, , ,	0.00001	/					
									
									-20 -10 0 10 20
									CNI MMF

Figure 3. Forest plot of glomerular filtration rate.


4. Discussion

Kidney transplantation, which is a form of RRT, is an efficient and preferable option for ESRD patients [3]. However, acute rejection and graft loss represent the clinical concerns after kidney transplantation (KT). Thus, safe and effective immunosuppressive therapy is needed to reduce graft failure caused by acute rejection and CNI-related nephrotoxicity in the most prevalent CNI-based immunosuppressive regimes [24, 25]. As a nonnephrotoxic immunosuppressive drug, MMF improves renal function without acute rejection after CNI withdrawal [26–28]. Moreover, two studies reported that MMF could have nephroprotective properties [29,30]. Recently, a meta-analysis suggested that CNI sparing strategies with

adjunctive MMF after KT can improve renal function, possibly reduce graft loss, and increase rejection rates only after elective CNI elimination [9]. Thus, MMF may enhance renal function but not increase rejection and nephrotoxicity, consequently improving patient and graft survival.

This is the first meta-analysis to evaluate the comparison and its timing between MMF and CNI as maintenance immunosuppression for kidney transplant recipients. We analyzed the data of 12 studies that compared the use of MMF and CNI as maintenance immunosuppression for kidney transplant recipients. The results of our present meta-analysis indicate that MMF significantly improved the GFR not only in the comparison performed after 3,

	MMF		CNI			Risk Ratio	Risk Ratio
Study or Subgroup				Total	Weight	M-H, Fixed, 95% C	I M-H. Fixed, 95% Cl
2.1.1 Comparison aft							
Albano 2012	0	14	0	13		Not estimable	
Asberg 2013	11	20	7	19	29.6%	1.49 [0.73, 3.04]	+
Cransberg 2007	1	21	0	23	2.0%	3.27 [0.14, 76.21]	
Hazzan 2005	0	54	0	54		Not estimable	
Mourer2012	5	79	7	79	28.8%	0.71 [0.24, 2.16]	
Schnulle 2002	1	44	0	40	2.2%	2.73 [0.11, 65.24]	
Stevens 2014	6	90	9	88	37.5%	0.65 [0.24, 1.75]	- - -
Subtotal (95% CI)		322		316	100.0%	1.01 [0.62, 1.67]	•
Total events	24		23				
Heterogeneity: Chi ² = 3	3.20. df = 4	(P = 0).53); l ² =	0%			
Test for overall effect:							
2.1.2 Comparison aft	er 3 mo of	CNI-b	ased the	rapy			
Hazzan 2005	0	54	0	54		Not estimable	
Schnulle 2002	1	44	0		100.0%	2.73 [0.11, 65.24]	_
Subtotal (95% CI)	1	98	0	94	100.0%	2.73 [0.11, 65.24]	
Total events	1	50	0	34	100.070	2.10 [0.11, 00.24]	
Heterogeneity: Not ap	-		0				
Test for overall effect:			3)				
rest for overall effect.	2 – 0.02 (F	- 0.5	5)				
2.1.3 Comparison aft							
Mourer2012	5	79	7	79	43.5%	0.71 [0.24, 2.16]	
Stevens 2014	6	90	9	88	56.5%	0.65 [0.24, 1.75]	
Subtotal (95% CI)		169		167	100.0%	0.68 [0.32, 1.42]	
Total events	11		16				
Heterogeneity: Chi ² =				0%			
Test for overall effect:	Z = 1.03 (P	9 = 0.30	D)				
2.1.4 Comparison aft	er 12 mo o	f CNI-	based th	erapy			
Albano 2012	0	14	0	13		Not estimable	
Asberg 2013	11	20	7	19	93.8%	1.49 [0.73, 3.04]	
Cransberg 2007	1	21	0	23	6.2%	3.27 [0.14, 76.21]	
Subtotal (95% CI)		55		55	100.0%	1.60 [0.80, 3.23]	◆
Total events	12		7				
Heterogeneity: Chi ² =		(P = 0)	$(63) \cdot l^2 =$	0%			
Test for overall effect:		•		070			
2.1.5 Comparison for	allograft o	lysfun	ction				
Dudley 2005	5	73	4	70	48.5%	1.20 [0.34, 4.28]	
Frimat 2006	1	70	1	31	16.5%	0.44 [0.03, 6.85]	
Mcgrath 2000	0	15	2	15	29.7%	0.20 [0.01, 3.85]	
Stoves 2004	1	13	2	16	29.7% 5.4%	3.64 [0.16, 82.62]	
Stoves 2004 Subtotal (95% CI)	1	171	0		5.4% 100.0%	0.91 [0.36, 2.33]	
	-	171	-	152	100.0%	0.81 [0.30, 2.33]	-
Total events	7	(D)	7	00/			
Heterogeneity: Chi ² = :	,	•		0%			
Test for overall effect:	∠ = 0.20 (P	· = 0.84	4)				
							0.001 0.1 1 10 1000
							MMF CNI



6, or 12 months of CNI-based therapy but also in the comparison of recipients with allograft dysfunction. This result suggested the ongoing benefits of using MMF instead of CNI not only in patients with deteriorating renal function but also in patients with stable renal function after KT regardless of the timing of the alternative. Interestingly, our present meta-analysis also found that MMF may

increase the risk of acute rejection in the comparison performed after 3 months of CNI-based therapy, but no increase was noted in the comparison performed after 6 or 12 months of CNI-based therapy. Taken together, the results of this analysis indicate that MMF offers similar efficiency as CNI after at least 6 months of CNI-based therapy as maintenance immunosuppression for kidney

	MMF		CNI			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
3.1.1 Comparison afte	er CNI-bas	sed the	erapy				
Albano 2012	0	14	1	13	8.3%	0.31 [0.01, 7.02]	
Asberg 2013	6	20	6	19	32.8%	0.95 [0.37, 2.44]	
Cransberg 2007	0	21	0	23		Not estimable	
Hazzan 2005	0	54	0	54		Not estimable	
Mourer2012	4	79	6	79	32.0%	0.67 [0.20, 2.27]	
Schnulle 2002	0	44	0	40		Not estimable	
Stevens 2014	3	90	5	88	26.9%	0.59 [0.14, 2.38]	
Subtotal (95% CI)		322		316	100.0%	0.71 [0.37, 1.35]	•
Total events	13		18				
Heterogeneity: Chi ² = 0).72, df = 3	3 (P = 0	.87); l² =	0%			
Test for overall effect: 2	Z = 1.04 (F	P = 0.30))				
3.1.2 Comparison afte	er 3 mo of	CNI-b	ased the	rapy			
Hazzan 2005	0	54	0	54		Not estimable	
Schnulle 2002	0	44	0	40		Not estimable	
Subtotal (95% CI)		98		94		Not estimable	
Total events	0		0				
Heterogeneity: Not app	olicable						
Test for overall effect: N	Not applica	able					
3.1.3 Comparison afte	er 6 mo of	CNI-b	ased the	rapy			
Mourer2012	4	79	6	79	54.3%	0.67 [0.20, 2.27]	
Stevens 2014	3	90	5	88	45.7%	0.59 [0.14, 2.38]	
	0	169		167	100.0%	0.63 [0.25, 1.58]	
Subtotal (95% CI)					100.0%	0.63 [0.25, 1.58]	•
Subtotal (95% CI) Total events	7	169	11	167	100.0%	0.63 [0.25, 1.58]	•
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2	7).02, df = 1	169 I (P = 0	11 0.89); I² =	167	100.0%	0.63 [0.25, 1.58]	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2	7).02, df = 2 Z = 0.98 (F	169 I (P = 0 P = 0.33	11 0.89); I² = 3)	167 0%	100.0%	0.63 [0.25, 1.58]	
Subtotal (95% CI) Fotal events Heterogeneity: Chi ² = 0 Fest for overall effect: 2 3.1.4 Comparison afte	7 0.02, df = 1 Z = 0.98 (F er 12 mo c	169 I (P = 0 P = 0.33	11 0.89); I ² = 3) based th	167 0% erapy			
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.4 Comparison afte Albano 2012	7 0.02, df = 7 Z = 0.98 (F er 12 mo c 0	169 I (P = 0 P = 0.33 of CNI- 14	11 0.89); I ² = 3) based the 1	167 0% erapy 13	20.1%	0.31 [0.01, 7.02]	
Subtotal (95% CI) Fotal events Heterogeneity: Chi ² = 0 Fest for overall effect: 2 8.1.4 Comparison afte Albano 2012 Asberg 2013	7 0.02, df = 7 Z = 0.98 (F er 12 mo o 0 6	169 I (P = 0 P = 0.33 of CNI- 14 20	11 0.89); ² = 3) based the 1 6	167 0% erapy 13 19		0.31 [0.01, 7.02] 0.95 [0.37, 2.44]	
Subtotal (95% CI) Fotal events Heterogeneity: Chi ² = 0 Fest for overall effect: 2 8.1.4 Comparison afte Albano 2012 Asberg 2013 Cransberg 2007	7 0.02, df = 7 Z = 0.98 (F er 12 mo c 0	169 P = 0.33 of CNI- 14 20 21	11 0.89); I ² = 3) based the 1	167 0% erapy 13 19 23	20.1% 79.9%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable	
Subtotal (95% CI) Fotal events Heterogeneity: Chi ² = 0 Fest for overall effect: 2 8.1.4 Comparison afte Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI)	7 0.02, df = 7 Z = 0.98 (F er 12 mo o 0 6 0	169 I (P = 0 P = 0.33 of CNI- 14 20	11 0.89); ² = 3) based the 1 6 0	167 0% erapy 13 19 23	20.1%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44]	
Subtotal (95% CI) Fotal events Heterogeneity: Chi ² = C Fest for overall effect: 2 3.1.4 Comparison afte Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Fotal events	7 0.02, df = 7 Z = 0.98 (F er 12 mo d 0 6 0 6	169 P = 0.33 of CNI- 14 20 21 55	11 0.89); I ² = 3) based the 1 6 0 7	167 0% erapy 13 19 23 55	20.1% 79.9%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable	
Subtotal (95% CI) Fotal events Heterogeneity: Chi ² = 0 Fest for overall effect: 2 3.1.4 Comparison afte Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Fotal events Heterogeneity: Chi ² = 0	7 0.02, df = 7 Z = 0.98 (F er 12 mo o 0 6 0 0 0 0 0 0 0 0 0 0 0 0 0	169 P = 0.33 of CNI- 14 20 21 55 I (P = 0	11 1.89); ² = 3) based th 1 6 0 7 1.50); ² =	167 0% erapy 13 19 23 55	20.1% 79.9%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2	7 0.02, df = 7 Z = 0.98 (F 0 6 0 0.46, df = 7 Z = 0.43 (F	169 I (P = 0 P = 0.33 of CNI- 14 20 21 55 I (P = 0 P = 0.63	11 $(.89); ^2 = 3)$ based th 1 6 0 7 $(.50); ^2 = 7)$	167 0% erapy 13 19 23 55	20.1% 79.9%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.5 Comparison for	7 0.02, df = 7 Z = 0.98 (F er 12 mo o 6 0 0.46, df = 7 Z = 0.43 (F allograft	169 I (P = 0 P = 0.33 of CNI- 14 20 21 55 I (P = 0 P = 0.63 dysfun	11 $(.89); ^2 = 3)$ based th 1 6 0 7 $(.50); ^2 = 7)$ ction	167 0% erapy 13 19 23 55 0%	20.1% 79.9% 100.0%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable 0.82 [0.34, 2.01]	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.5 Comparison for Dudley 2005	7 0.02, df = 7 Z = 0.98 (F er 12 mo o 0 6 0 0 6 0.46, df = 7 Z = 0.43 (F allograft 3	169 1 (P = 0 2 = 0.33 of CNI- 14 20 21 55 1 (P = 0 P = 0.67 dysfun 73	11 $(.89); ^2 = 3)$ based th 1 6 0 7 $(.50); ^2 = 7)$ ction 0	167 0% erapy 13 19 23 55 0%	20.1% 79.9%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable 0.82 [0.34, 2.01] 6.72 [0.35, 127.71]	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.5 Comparison for Dudley 2005 Frimat 2006	7 0.02, df = 7 Z = 0.98 (F er 12 mo o 6 0 0 6 0.46, df = 7 Z = 0.43 (F allograft 3 0	169 1 (P = 0 2 = 0.33 of CNI- 14 20 21 55 1 (P = 0 P = 0.67 dysfun 73 70	11 $(.89); ^2 = 3)$ based th 1 6 0 7 $(.50); ^2 = 7)$ ction 0 0	167 0% erapy 13 19 23 55 0% 70 31	20.1% 79.9% 100.0%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable 0.82 [0.34, 2.01] 6.72 [0.35, 127.71] Not estimable	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.5 Comparison for Dudley 2005 Frimat 2006 Mcgrath 2001	7 0.02, df = 7 Z = 0.98 (F er 12 mo o 6 0.46, df = 7 Z = 0.43 (F allograft 3 0 0	169 I (P = 0 P = 0.33 of CNI- 14 20 21 55 I (P = 0 P = 0.63 I (P = 0 P = 0.63 73 70 15	11 $(.89); ^2 = 3)$ based the 1 6 0 7 $(.50); ^2 = 7)$ ction 0 0 0 0	167 0% erapy 13 19 23 55 0% 70 31 15	20.1% 79.9% 100.0%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable 0.82 [0.34, 2.01] 6.72 [0.35, 127.71] Not estimable Not estimable	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.5 Comparison for Dudley 2005 Frimat 2006 Mcgrath 2001 Stoves 2004	7 0.02, df = 7 Z = 0.98 (F er 12 mo o 6 0 0 6 0.46, df = 7 Z = 0.43 (F allograft 3 0	169 I (P = 0 P = 0.33 of CNI- 14 20 21 55 I (P = 0 P = 0.63 dysfun 73 70 15 13	11 $(.89); ^2 = 3)$ based th 1 6 0 7 $(.50); ^2 = 7)$ ction 0 0	167 0% erapy 13 19 23 55 0% 70 31 15 16	20.1% 79.9% 100.0%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable 0.82 [0.34, 2.01] 6.72 [0.35, 127.71] Not estimable Not estimable Not estimable	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.5 Comparison for Dudley 2005 Frimat 2006 Mcgrath 2001 Stoves 2004 Subtotal (95% CI)	7 0.02, df = 7 Z = 0.98 (F er 12 mo o 0 6 0.46, df = 7 Z = 0.43 (F allograft 3 0 0 0 0	169 I (P = 0 P = 0.33 of CNI- 14 20 21 55 I (P = 0 P = 0.63 I (P = 0 P = 0.63 73 70 15	11 $(.89); ^2 = 3)$ based the 1 6 0 7 $(.50); ^2 = 7)$ ction 0 0 0 0 0 0 0	167 0% erapy 13 19 23 55 0% 70 31 15 16	20.1% 79.9% 100.0%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable 0.82 [0.34, 2.01] 6.72 [0.35, 127.71] Not estimable Not estimable	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.5 Comparison for Dudley 2005 Frimat 2006 Mcgrath 2001 Stoves 2004 Subtotal (95% CI) Total events	7 0.02, df = 7 Z = 0.98 (F er 12 mo o 0 6 0.46, df = 7 Z = 0.43 (F allograft 3 0 0 0 3	169 I (P = 0 P = 0.33 of CNI- 14 20 21 55 I (P = 0 P = 0.63 dysfun 73 70 15 13	11 $(.89); ^2 = 3)$ based the 1 6 0 7 $(.50); ^2 = 7)$ ction 0 0 0 0	167 0% erapy 13 19 23 55 0% 70 31 15 16	20.1% 79.9% 100.0%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable 0.82 [0.34, 2.01] 6.72 [0.35, 127.71] Not estimable Not estimable	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.5 Comparison for Dudley 2005 Frimat 2006 Mcgrath 2001 Stoves 2004 Subtotal (95% CI) Total events Heterogeneity: Not app	7 0.02, df = 7 Z = 0.98 (F er 12 mo o 0 6 0.46, df = 7 Z = 0.43 (F allograft 3 0 0 0 3 slicable	169 1 (P = 0 2 = 0.3: of CNI- 14 20 21 55 1 (P = 0 2 = 0.6: dysfun 73 70 15 13 171	11 $(.89); ^2 = 3)$ based the 1 6 0 7 $(.50); ^2 = 7)$ ction 0 0 0 0 0 0 0	167 0% erapy 13 19 23 55 0% 70 31 15 16	20.1% 79.9% 100.0%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable 0.82 [0.34, 2.01] 6.72 [0.35, 127.71] Not estimable Not estimable	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0	7 0.02, df = 7 Z = 0.98 (F er 12 mo o 0 6 0.46, df = 7 Z = 0.43 (F allograft 3 0 0 0 3 slicable	169 1 (P = 0 2 = 0.3: of CNI- 14 20 21 55 1 (P = 0 2 = 0.6: dysfun 73 70 15 13 171	11 $(.89); ^2 = 3)$ based the 1 6 0 7 $(.50); ^2 = 7)$ ction 0 0 0 0 0 0 0	167 0% erapy 13 19 23 55 0% 70 31 15 16	20.1% 79.9% 100.0%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable 0.82 [0.34, 2.01] 6.72 [0.35, 127.71] Not estimable Not estimable	
Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2 3.1.5 Comparison for Dudley 2005 Frimat 2006 Mcgrath 2001 Stoves 2004 Subtotal (95% CI) Total events Heterogeneity: Not app	7 0.02, df = 7 Z = 0.98 (F er 12 mo o 0 6 0.46, df = 7 Z = 0.43 (F allograft 3 0 0 0 3 slicable	169 1 (P = 0 2 = 0.3: of CNI- 14 20 21 55 1 (P = 0 2 = 0.6: dysfun 73 70 15 13 171	11 $(.89); ^2 = 3)$ based the 1 6 0 7 $(.50); ^2 = 7)$ ction 0 0 0 0 0 0 0	167 0% erapy 13 19 23 55 0% 70 31 15 16	20.1% 79.9% 100.0%	0.31 [0.01, 7.02] 0.95 [0.37, 2.44] Not estimable 0.82 [0.34, 2.01] 6.72 [0.35, 127.71] Not estimable Not estimable	

Figure 5. Forest plot of mortality.

transplant recipients, while MMF appears safer than CNI, as reflected by its protective effects on renal function. However, this finding must be further demonstrated by more large-scale, high-quality, and long-term studies. In addition, MMF is associated with a reduced incidence of proteinuria, whereas the opposite effects were noted for anemia and diarrhea compared to CNI.

Several limitations to this meta-analysis should be noted. Above all, most of the included trials had small

samples and were not multicenter RCTs. In addition, no studies were double-blinded. Furthermore, data from some studies were unavailable or deficient and could not be obtained from the original authors, which may weaken the evidence of the results. Moreover, given that a few studies in each subgroup and several studies with a short duration, the efficacy and safety of MMF for renal transplant recipients must be proven by further large-scale and long-term studies. Finally, some heterogeneity in clinical

	MMF		CNI			Risk Ratio	Risk Ratio
Study or Subgroup		Total			Woight		
4.1.1 Comparison afte				TOtal	weight	WI-II, FIXed, 35% CI	MI-II, FIXEd, 3576 CI
Albano 2012	0	14	1 1 1	13	7.0%	0.21 [0.01 7.02]	
	6	20	0	19	2.3%	0.31 [0.01, 7.02]	
Asberg 2013	3	20	-	23		12.38 [0.75, 205.75]	
Cransberg 2007			2		8.6%	1.64 [0.30, 8.89]	
Hazzan 2005	10	54	3	54	13.5%	3.33 [0.97, 11.45]	
Mourer2012	4	79	2	79	9.0%	2.00 [0.38, 10.61]	
Schnulle 2002	5	44	2	40	9.4%	2.27 [0.47, 11.07]	
Stevens 2014	17	90	11	88	50.1%	1.51 [0.75, 3.04]	
Subtotal (95% CI)		322		316	100.0%	2.05 [1.27, 3.32]	-
Total events	45		21				
Heterogeneity: Chi ² = 4				0%			
Test for overall effect: Z	Z = 2.92 (P	= 0.00)3)				
4.1.2 Comparison afte	er 3 mo of	CNI-ba	ased the	rapy			
Hazzan 2005	10	54	3	54	58.9%	3.33 [0.97, 11.45]	
Schnulle 2002	5	44	2	40	41.1%	2.27 [0.47, 11.07]	+
Subtotal (95% CI)		98		94	100.0%	2.90 [1.10, 7.64]	
Total events	15		5				
Heterogeneity: Chi ² = 0		(P = 0)	.71); l ² =	0%			
Test for overall effect: Z							
4.1.3 Comparison afte	er 6 mo of	CNI-b	ased the	rapy			
Mourer2012	4	79	2	79	15.2%	2.00 [0.38, 10.61]	- -
Stevens 2014	17	90	11	88	84.8%	1.51 [0.75, 3.04]	
Subtotal (95% CI)		169		167	100.0%	1.59 [0.83, 3.02]	
Subtotal (95% CI)	21	169	13	167	100.0%	1.59 [0.83, 3.02]	
Total events	21 0.09 df = 1		13 76): 1² =		100.0%	1.59 [0.83, 3.02]	-
Total events Heterogeneity: Chi ² = 0	0.09, df = 1	(P = 0	.76); l² =		100.0%	1.59 [0.83, 3.02]	•
Total events	0.09, df = 1	(P = 0	.76); l² =		100.0%	1.59 [0.83, 3.02]	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z	0.09, df = 1 Z = 1.40 (P	(P = 0 = 0.16	.76); I² = 6)	0%	100.0%	1.59 [0.83, 3.02]	
Total events Heterogeneity: Chi ² = 0	0.09, df = 1 Z = 1.40 (P	(P = 0 = 0.16	.76); I² = 6)	0%	100.0% 39.1%	1.59 [0.83, 3.02] 0.31 [0.01, 7.02]	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison afte	0.09, df = 1 Z = 1.40 (P er 12 mo o	(P = 0 = 0.16 f CNI-I	.76); l² = 5) based th	0% erapy	39.1%		
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison afte Albano 2012	0.09, df = 1 Z = 1.40 (P er 12 mo o 0	(P = 0 = 0.16 f CNI-1 14	.76); I² = 5) based th 1	0% erapy 13	39.1%	0.31 [0.01, 7.02]	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison afte Albano 2012 Asberg 2013	0.09, df = 1 Z = 1.40 (P er 12 mo o 0 6	(P = 0 = 0.16 f CNI-1 14 20	.76); I ² = 5) based th 1 0	0% erapy 13 19	39.1% 12.9%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75]	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison afte Albano 2012 Asberg 2013 Cransberg 2007	0.09, df = 1 Z = 1.40 (P er 12 mo o 0 6	(P = 0 = 0.16 f CNI-I 14 20 21	.76); I ² = 5) based th 1 0	0% erapy 13 19 23	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89]	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison afte Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI)).09, df = 1 Z = 1.40 (P er 12 mo o 0 6 3 9	(P = 0 = 0.16 f CNI-1 14 20 21 55	.76); I ² = 5) based th 1 0 2 3	0% erapy 13 19 23 55	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89]	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison afte Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events	0.09, df = 1 Z = 1.40 (P er 12 mo o 0 6 3 9 3.20, df = 2	(P = 0 = 0.16 f CNI-1 14 20 21 55 (P = 0	.76); l ² = 5) based th 1 0 2 .20); l ² =	0% erapy 13 19 23 55	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89]	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 3	0.09, df = 1 Z = 1.40 (P er 12 mo o 0 6 3 9 9.20, df = 2 Z = 1.60 (P	(P = 0 = 0.16 f CNI-1 14 20 21 55 (P = 0 = 0.11	.76); ² = 5) based th 1 0 2 .20); ² = 1)	0% erapy 13 19 23 55	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89]	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 3 Test for overall effect: Z 4.1.5 Comparison for a	0.09, df = 1 Z = 1.40 (P er 12 mo o 0 6 3 9 9.20, df = 2 Z = 1.60 (P allograft o	(P = 0 = 0.16 14 20 21 55 (P = 0 = 0.11	.76); l ² = 5) pased th 1 0 2 .20); l ² = 1) ction	0% erapy 13 19 23 55 38%	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89] 2.51 [0.81, 7.72]	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 3 Test for overall effect: Z 4.1.5 Comparison for a Dudley 2005	0.09, df = 1 Z = 1.40 (P er 12 mo o 0 6 3 9 0.20, df = 2 Z = 1.60 (P allograft c 0	(P = 0 = 0.16 14 20 21 55 (P = 0 = 0.11 Iysfun 73	.76); l ² = 5) pased th 1 0 2 .20); l ² = 1) ction 0	0% erapy 13 19 23 55 38% 70	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89] 2.51 [0.81, 7.72] Not estimable	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 3 Test for overall effect: Z 4.1.5 Comparison for a Dudley 2005 Frimat 2006	0.09, df = 1 Z = 1.40 (P r = 12 mo o 0 6 3 9 0.20, df = 2 Z = 1.60 (P allograft c 0 0	(P = 0) = 0.16 f CNI-1 14 20 21 55 (P = 0) = 0.11 Nysfun 73 70	.76); l ² = based th 1 0 2 .20); l ² =) ction 0 0	0% eerapy 13 19 23 55 38% 70 31	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89] 2.51 [0.81, 7.72] Not estimable Not estimable	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison afte Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 3 Test for overall effect: Z 4.1.5 Comparison for a Dudley 2005 Frimat 2006 Mcgrath 2001	0.09, df = 1 Z = 1.40 (P er 12 mo o 0 6 3 9 0.20, df = 2 Z = 1.60 (P allograft d 0 0 0 0	(P = 0 = 0.16 14 20 21 55 (P = 0 = 0.11 1ysfun 73 70 15	.76); l ² = based th 1 0 2 .20); l ² = 1) ction 0 0 0 0	0% eerapy 13 19 23 55 38% 70 31 15	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89] 2.51 [0.81, 7.72] Not estimable Not estimable Not estimable	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = 3 Test for overall effect: Z 4.1.5 Comparison for a Dudley 2005 Frimat 2006 Mcgrath 2001 Stoves 2004	0.09, df = 1 Z = 1.40 (P r = 12 mo o 0 6 3 9 0.20, df = 2 Z = 1.60 (P allograft c 0 0	(P = 0 = 0.16 f CNI-1 20 21 55 (P = 0 = 0.11 lysfun 73 70 15 13	.76); l ² = based th 1 0 2 .20); l ² =) ction 0 0	0% 13 19 23 55 38% 70 31 15 16	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89] 2.51 [0.81, 7.72] Not estimable Not estimable Not estimable	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 3 Test for overall effect: Z 4.1.5 Comparison for 3 Dudley 2005 Frimat 2006 Mcgrath 2001 Stoves 2004 Subtotal (95% CI)	0.09, df = 1 Z = 1.40 (P 2 12 mo o 0 6 3 8.20, df = 2 Z = 1.60 (P allograft o 0 0 0 0	(P = 0 = 0.16 14 20 21 55 (P = 0 = 0.11 1ysfun 73 70 15	.76); l ² = based th 1 0 2 .20); l ² =) ction 0 0 0 0 0	0% eerapy 13 19 23 55 38% 70 31 15	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89] 2.51 [0.81, 7.72] Not estimable Not estimable Not estimable	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 3 Test for overall effect: Z 4.1.5 Comparison for 2 Dudley 2005 Frimat 2006 Mcgrath 2001 Stoves 2004 Subtotal (95% CI) Total events	0.09, df = 1 Z = 1.40 (P er 12 mo o 0 6 3 9 9.20, df = 2 Z = 1.60 (P allograft d 0 0 0 0 0	(P = 0 = 0.16 f CNI-1 20 21 55 (P = 0 = 0.11 lysfun 73 70 15 13	.76); l ² = based th 1 0 2 .20); l ² = 1) ction 0 0 0 0	0% 13 19 23 55 38% 70 31 15 16	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89] 2.51 [0.81, 7.72] Not estimable Not estimable Not estimable	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 3 Test for overall effect: Z 4.1.5 Comparison for a Dudley 2005 Frimat 2006 Mcgrath 2001 Stoves 2004 Subtotal (95% CI) Total events Heterogeneity: Not app	0.09, df = 1 Z = 1.40 (P er 12 mo o 0 6 3 9 9.20, df = 2 Z = 1.60 (P allograft o 0 0 0 0 0 0	(P = 0 = 0.16 f CNI-1 20 21 55 (P = 0 = 0.11 73 70 15 13 0	.76); l ² = based th 1 0 2 .20); l ² =) ction 0 0 0 0 0	0% 13 19 23 55 38% 70 31 15 16	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89] 2.51 [0.81, 7.72] Not estimable Not estimable Not estimable	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 3 Test for overall effect: Z 4.1.5 Comparison for 2 Dudley 2005 Frimat 2006 Mcgrath 2001 Stoves 2004 Subtotal (95% CI) Total events	0.09, df = 1 Z = 1.40 (P er 12 mo o 0 6 3 9 9.20, df = 2 Z = 1.60 (P allograft o 0 0 0 0 0 0	(P = 0 = 0.16 f CNI-1 20 21 55 (P = 0 = 0.11 73 70 15 13 0	.76); l ² = based th 1 0 2 .20); l ² =) ction 0 0 0 0 0	0% 13 19 23 55 38% 70 31 15 16	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89] 2.51 [0.81, 7.72] Not estimable Not estimable Not estimable	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 3 Test for overall effect: Z 4.1.5 Comparison for a Dudley 2005 Frimat 2006 Mcgrath 2001 Stoves 2004 Subtotal (95% CI) Total events Heterogeneity: Not app	0.09, df = 1 Z = 1.40 (P er 12 mo o 0 6 3 9 9.20, df = 2 Z = 1.60 (P allograft o 0 0 0 0 0 0	(P = 0 = 0.16 f CNI-1 20 21 55 (P = 0 = 0.11 73 70 15 13 0	.76); l ² = based th 1 0 2 .20); l ² =) ction 0 0 0 0 0	0% 13 19 23 55 38% 70 31 15 16	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89] 2.51 [0.81, 7.72] Not estimable Not estimable Not estimable	
Total events Heterogeneity: Chi ² = 0 Test for overall effect: Z 4.1.4 Comparison after Albano 2012 Asberg 2013 Cransberg 2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 3 Test for overall effect: Z 4.1.5 Comparison for a Dudley 2005 Frimat 2006 Mcgrath 2001 Stoves 2004 Subtotal (95% CI) Total events Heterogeneity: Not app	0.09, df = 1 Z = 1.40 (P er 12 mo o 0 6 3 9 9.20, df = 2 Z = 1.60 (P allograft o 0 0 0 0 0 0	(P = 0 = 0.16 f CNI-1 20 21 55 (P = 0 = 0.11 73 70 15 13 0	.76); l ² = based th 1 0 2 .20); l ² =) ction 0 0 0 0 0	0% 13 19 23 55 38% 70 31 15 16	39.1% 12.9% 48.1%	0.31 [0.01, 7.02] 12.38 [0.75, 205.75] 1.64 [0.30, 8.89] 2.51 [0.81, 7.72] Not estimable Not estimable Not estimable	

Figure 6. Forest plot of acute rejection (biopsy proven).

features, such as the immunosuppressive therapy and drug dosages, was noted; however, the included studies had similar baseline characteristics. Thus, more large-scale, high-quality, and multicenter RCTs with longer duration times and reduced heterogeneity are required to address the above limitations.

In conclusion, the result of our present meta-analysis is that MMF offers similar efficiency as CNI after at least 6 months of CNI-based therapy as maintenance immunosuppression for kidney transplant recipients, while MMF appears safer than CNI, as reflected by its protective effects on renal function. It is suggested that MMF followed at least 6 months of CNI-based therapy is an effective maintenance immunosuppressive regimen for kidney transplant recipients to improve renal function but not increase rejection. However, these results must be confirmed in future studies.

Outcome	Studies	MMF group	CNI group	Heterogeneity (P, I ²)	Statistical method	Effect estimate	P value
Infection	7	156/384	117/339	0.006, 66%	Risk ratio (M-H, Random, 95%CI)	1.19(0.83, 1.73)	0.34
Anemia	5	56/250	20/211	0.61, 0%	Risk ratio (M-H, Fixed, 95%CI)	2.36 (1.46, 3.81)	0.0005
Diarrhea	5	54/281	8/235	0.32, 15%	Risk ratio (M-H, Fixed, 95%CI)	5.36 (2.66, 10.80)	0.00001
NODAT	5	25/241	28/238	0.77, 0%	Risk ratio (M-H, Fixed, 95%CI)	0.86 (0.53, 1.42)	0.56
Malignancies	4	12/254	13/198	0.77, 0%	Risk ratio (M-H, Fixed, 95%CI)	0.84 (0.39, 1.84)	0.66
Proteinuria	3	34/139	30/100	0.38, 0%	Risk ratio (M-H, Fixed, 95%CI)	0.63 (0.43, 0.92)	0.02
Hypertension	2	5/88	11/85	0.35, 0%	Risk Ratio (M-H, Fixed, 95%CI)	0.46 (0.17, 1.23)	0.12

Table 2. Summary of adverse events of included studies comparing MMF with CNI groups as maintenance immunosuppression after kidney transplantation.

MMF, mycophenolate mofetil; CNI, calcineurin inhibitor; NODAT, new-onset diabetes mellitus after transplantation.




Figure 7. Funnel plot for acute rejection.

Acknowledgement/disclaimers/conflict of interest This study was supported by Scientific Research Fund Project of Hunan Provincial Health Commission (20201940) and The Natural Science Foundation of Hunan Province (2018JJ3474).

No potential conflict of interest was reported by the authors.

Informed consent

Not required.

References

- Anand S, Bitton A, Gaziano T. The gap between estimated incidence of end-stage renal disease and use of therapy. PloS One 2013; 8 (8): e72860-e72860. doi: 10.1371/journal.pone.0072860
- Bongiovanni I, Couillerot-Peyrondet AL, Sambuc C, Dantony E, Elsensohn MH et al. [Cost-effectiveness analysis of various strategies of end-stage renal disease patients' care in France]. Nephrologie & Therapeutique 2016;12 (2):104-115. doi: 10.1016/j.nephro.2015.10.004
- KDIGO clinical practice guideline for the care of kidney transplant recipients. American Journal of Transplantation 2009; 9 Suppl 3: S1-155. doi: 10.1111/j.1600-6143.2009.02834.x
- Yildirim A. The importance of patient satisfaction and healthrelated quality of life after renal transplantation. Transplantation Proceedings 2006; 38 (9): 2831-2834. doi: 10.1016/j. transproceed.2006.08.162
- Wit GAD, Ramsteijn PG, Charro FTD. Economic evaluation of end stage renal disease treatment. Health Policy 1998; 44 (3): 215-232. doi: 10.1016/s0168-8510(98)00017-7
- Pascual M, Theruvath T, Kawai T, Tolkoffrubin N, Cosimi AB. Strategies to improve outcomes after renal transplantation. New England Journal of Medicine 2002; 346 (8): 580-590. doi: 10.1056/NEJMra011295
- Shipkova M, Armstrong VW, Oellerich M, Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opinion on Drug Metabolism & Toxicology 2005; 1 (3): 505-526. doi: 10.1517/17425255.1.3.505
- Ciancio G, Miller J, Gonwa TA. Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 2005; 80 (2 Suppl): S191-200. doi: 10.1097/01. tp.0000187035.22298.ba
- Moore J, Middleton L, Cockwell P, Adu D, Ball S et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation 2009; 87 (4): 591-605. doi: 10.1097/TP.0b013e318195a421
- Anders Å, Apeland T, Reisaeter AV, Foss A, Leivestad T et al. Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation - results from an aborted trial. Clinical Transplantation 2013; 27 (2): E151–E156. doi: 10.1111/ctr.12076
- Mourer JS, Jd H, van Zwet EW, Mallat MJ, Dubbeld J et al. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. Transplantation 2012; 93 (9): 887-894. doi: 10.1097/ TP.0b013e31824ad60a
- Hazzan M, Labalette M, Copin MC, Glowacki F, Provôt F et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. Journal of the American Society of Nephrology 2005; 16 (8): 2509-2516. doi: 10.1681/ASN.2005030312
- Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration 2014.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002; 21(11): 1539-1558. doi: 10.1002/sim.1186

- Hoerning A, Köhler S, Lu J, Fu J, Tebbe B et al. Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4 + T cell subsets circulating in the peripheral blood of renal transplant recipients. Clinical and Experimental Immunology 2012; 168 (2): 251-259. doi: 10.1111/j.1365-2249.2012.04571.x
- Schnuelle P, Jh VDH, Tegzess A, Verburgh CA, Paul LC et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. Journal of the American Society of Nephrology 2002; 13 (2): 536-543. doi: 10.1089/089277902753483745
- Stevens RB, Foster KW, Miles CD, Kalil AC, Florescu DF et al. A Randomized 2x2 factorial clinical trial of renal transplantation: steroid-free maintenance immunosuppression with calcineurin inhibitor withdrawal after six months associates with improved renal function and reduced chronic histopathology. Plos One 2015; 10 (10): e0139247. doi: 10.1371/journal. pone.0139247
- Albano L, Alamartine E, Toupance O, Moulin B, Merville P et al. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, openlabel multicenter study. Annals of Transplantation Quarterly of the Polish Transplantation Society 2012; 17 (17): 58-67. doi: 10.12659/aot.882637
- Cransberg K, Cornelissen M, Lilien M, Van HK, Davin JC et al. Maintenance immunosuppression with mycophenolate mofetil and corticosteroids in pediatric kidney transplantation: temporary benefit but not without risk. Transplantation 2007; 83 (8): 1041-1047. doi: 10.1097/01.tp.0000260146.57898.9c
- Dudley C, Pohanka E, Riad H, Dedochova J, Wijngaard P et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005; 79 (4): 466-475. doi: 10.1097/01.tp.0000151632.21551.00
- 21. Frimat L, Cassutoviguier E, Charpentier B, Noël C, Provôt F et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. American Journal of Transplantation 2006; 6 (11): 2725-2734. doi: 10.1111/j.1600-6143.2006.01535.x
- 22. Mcgrath JS, Shehata M. Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution. Transplantation Proceedings 2001; 33 (3): 2193-2195. doi: 10.1016/s0041-1345(01)01939-x
- 23. Stoves J, Newstead CG, Baczkowski AJ, Owens G, Paraoan M et al. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Nephrology Dialysis Transplantation 2004; 19 (8): 2113-2120. doi: 10.1093/ndt/gfh188
- Solez K, ., Vincenti F, ., Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66 (12): 1736-1740. doi: 10.1097/00007890-199812270-00029

- Goldfarb DA. The natural history of chronic allograft nephropathy. Journal of Urology 2005; 173 (6): 2106. doi: 10.1016/ S0022-5347(05)60253-4
- Houde I, Isenring P, Boucher D, Noel R, Lachanche JG. Mycophenolate mofetil, an alternative to cyclosporine A for longterm immunosuppression in kidney transplantation? Transplantation 2000; 70 (8): 1251-1253. doi: 10.1097/00007890-200010270-00023
- 27. Schrama YC, Joles JA, Van TA, Boer P, Koomans HA et al. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplantation 2000; 69 (3): 376. doi: 10.1097/00007890-200002150-00012
- Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. American Journal of Transplantation 2004; 4 (4): 655-662. doi: 10.1111/j.1600-6143.2004.00404.x

- 29. Gonzalez MM, Seron D, Garcia dMR, Carrera M, Sola E et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A followup study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004; 77 (2): 215-220. doi: 10.1097/01.TP.0000100684.59784.FF
- 30. Merville P, Bergé F, Deminière C, Morel D, Chong G et al. Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. American Journal of Transplantation 2004; 4 (11): 1769-1775. doi: 10.1111/j.1600-6143.2004.00533.x